Literature DB >> 19773441

MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Yunqing Li1, Fadila Guessous, Ying Zhang, Charles Dipierro, Benjamin Kefas, Elizabeth Johnson, Lukasz Marcinkiewicz, Jinmai Jiang, Yanzhi Yang, Thomas D Schmittgen, Beatriz Lopes, David Schiff, Benjamin Purow, Roger Abounader.   

Abstract

MicroRNA-34a (miR-34a) is a transcriptional target of p53 that is down-regulated in some cancer cell lines. We studied the expression, targets, and functional effects of miR-34a in brain tumor cells and human gliomas. Transfection of miR-34a down-regulated c-Met in human glioma and medulloblastoma cells and Notch-1, Notch-2, and CDK6 protein expressions in glioma cells. miR-34a expression inhibited c-Met reporter activities in glioma and medulloblastoma cells and Notch-1 and Notch-2 3'-untranslated region reporter activities in glioma cells and stem cells. Analysis of human specimens showed that miR-34a expression is down-regulated in glioblastoma tissues as compared with normal brain and in mutant p53 gliomas as compared with wild-type p53 gliomas. miR-34a levels in human gliomas inversely correlated to c-Met levels measured in the same tumors. Transient transfection of miR-34a into glioma and medulloblastoma cell lines strongly inhibited cell proliferation, cell cycle progression, cell survival, and cell invasion, but transfection of miR-34a into human astrocytes did not affect cell survival and cell cycle status. Forced expression of c-Met or Notch-1/Notch-2 transcripts lacking the 3'-untranslated region sequences partially reversed the effects of miR-34a on cell cycle arrest and cell death in glioma cells and stem cells, respectively. Also, transient expression of miR-34a in glioblastoma cells strongly inhibited in vivo glioma xenograft growth. Together, these findings represent the first comprehensive analysis of the role of miR-34a in gliomas. They show that miR-34a suppresses brain tumor growth by targeting c-Met and Notch. The results also suggest that miR-34a could serve as a potential therapeutic agent for brain tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19773441      PMCID: PMC2756313          DOI: 10.1158/0008-5472.CAN-09-0529

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells.

Authors:  C Welch; Y Chen; R L Stallings
Journal:  Oncogene       Date:  2007-02-12       Impact factor: 9.867

2.  The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.

Authors:  Yunqing Li; Bachchu Lal; Sherwin Kwon; Xing Fan; Usha Saldanha; Thomas E Reznik; Eric B Kuchner; Charles Eberhart; John Laterra; Roger Abounader
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

3.  Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells.

Authors:  Hiroshi Tazawa; Naoto Tsuchiya; Masashi Izumiya; Hitoshi Nakagama
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

4.  PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

Authors:  Yunqing Li; Fadila Guessous; Sherwin Kwon; Manish Kumar; Opeyemi Ibidapo; Lauren Fuller; Elizabeth Johnson; Bachchu Lal; Isa Hussaini; Yongde Bao; John Laterra; David Schiff; Roger Abounader
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

5.  Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest.

Authors:  Fang Sun; Hanjiang Fu; Qin Liu; Yi Tie; Jie Zhu; Ruiyun Xing; Zhixian Sun; Xiaofei Zheng
Journal:  FEBS Lett       Date:  2008-04-10       Impact factor: 4.124

6.  microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma.

Authors:  Benjamin Kefas; Jakub Godlewski; Laurey Comeau; Yunqing Li; Roger Abounader; Michael Hawkinson; Jeongwu Lee; Howard Fine; E Antonio Chiocca; Sean Lawler; Benjamin Purow
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

7.  A microRNA component of the p53 tumour suppressor network.

Authors:  Lin He; Xingyue He; Lee P Lim; Elisa de Stanchina; Zhenyu Xuan; Yu Liang; Wen Xue; Lars Zender; Jill Magnus; Dana Ridzon; Aimee L Jackson; Peter S Linsley; Caifu Chen; Scott W Lowe; Michele A Cleary; Gregory J Hannon
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

8.  Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

Authors:  Valery Tarasov; Peter Jung; Berlinda Verdoodt; Dmitri Lodygin; Alexey Epanchintsev; Antje Menssen; Gunter Meister; Heiko Hermeking
Journal:  Cell Cycle       Date:  2007-05-11       Impact factor: 4.534

9.  Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma.

Authors:  Yunqing Li; Fadila Guessous; Elizabeth B Johnson; Charles G Eberhart; Xiao-Nan Li; Qing Shu; Shongshan Fan; Bachchu Lal; John Laterra; David Schiff; Roger Abounader
Journal:  Lab Invest       Date:  2007-12-03       Impact factor: 5.662

10.  Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.

Authors:  Nina Raver-Shapira; Efi Marciano; Eti Meiri; Yael Spector; Nitzan Rosenfeld; Neta Moskovits; Zvi Bentwich; Moshe Oren
Journal:  Mol Cell       Date:  2007-05-31       Impact factor: 17.970

View more
  274 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 2.  Prostate cancer stem cell biology.

Authors:  C Yu; Z Yao; Y Jiang; E T Keller
Journal:  Minerva Urol Nefrol       Date:  2012-03       Impact factor: 3.720

3.  miRNA-34c regulates Notch signaling during bone development.

Authors:  Yangjin Bae; Tao Yang; Huan-Chang Zeng; Philippe M Campeau; Yuqing Chen; Terry Bertin; Brian C Dawson; Elda Munivez; Jianning Tao; Brendan H Lee
Journal:  Hum Mol Genet       Date:  2012-04-12       Impact factor: 6.150

4.  Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis.

Authors:  Claire M Payne; Cheray Crowley-Skillicorn; Carol Bernstein; Hana Holubec; Harris Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2011-05-03

Review 5.  The emerging functions of the p53-miRNA network in stem cell biology.

Authors:  Chao-Po Lin; Yong Jin Choi; Geoffrey G Hicks; Lin He
Journal:  Cell Cycle       Date:  2012-06-01       Impact factor: 4.534

6.  Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma.

Authors:  Chenzhuo Feng; Ying Zhang; Jinbo Yin; Jun Li; Roger Abounader; Zhiyi Zuo
Journal:  Neuro Oncol       Date:  2014-02-12       Impact factor: 12.300

7.  MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC).

Authors:  Jiali Zhang; Yu Wang; Xinming Chen; Yi Zhou; Fangyan Jiang; Jirong Chen; Li Wang; Wen-Feng Zhang
Journal:  Oncotarget       Date:  2015-04-10

8.  microRNA-34a promotes DNA damage and mitotic catastrophe.

Authors:  Alexander V Kofman; Jungeun Kim; So Yeon Park; Evan Dupart; Christopher Letson; Yongde Bao; Kai Ding; Quan Chen; David Schiff; James Larner; Roger Abounader
Journal:  Cell Cycle       Date:  2013-09-19       Impact factor: 4.534

9.  Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma.

Authors:  Xinlong Ma; Koji Yoshimoto; Yaulei Guan; Nobuhiro Hata; Masahiro Mizoguchi; Noriaki Sagata; Hideki Murata; Daisuke Kuga; Toshiyuki Amano; Akira Nakamizo; Tomio Sasaki
Journal:  Neuro Oncol       Date:  2012-07-27       Impact factor: 12.300

Review 10.  Eradicating Cancer Stem Cells: Concepts, Issues, and Challenges.

Authors:  Gurpreet Kaur; Praveen Sharma; Nilambra Dogra; Sandeep Singh
Journal:  Curr Treat Options Oncol       Date:  2018-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.